Severe Late-Onset Neutropenia in a Patient With Multiple Sclerosis Treated With Ocrelizumab.
Publication/Presentation Date
12-1-2025
Abstract
Ocrelizumab, a humanised monoclonal antibody targeting cluster of differentiation 20 (CD20), is widely used to treat multiple sclerosis (MS). While it is effective in reducing relapse rates, adverse effects such as late-onset neutropenia can pose significant clinical challenges. We report the case of a 36-year-old female with a history of relapsing-remitting MS (RRMS) who developed severe neutropenia following ocrelizumab administration. The patient presented with fever, fatigue, and oral aphthous ulcers, with laboratory tests confirming an absolute neutrophil count (ANC) of 0.11 × 10⁹/L. Prompt initiation of broad-spectrum antibiotics and granulocyte colony-stimulating factor (G-CSF) resulted in significant clinical improvement. This case highlights the importance of monitoring blood counts in patients receiving ocrelizumab and the need for timely intervention for late-onset neutropenia (LON).
Volume
17
Issue
12
First Page
99574
Last Page
99574
ISSN
2168-8184
Published In/Presented At
Mansour, M. K., Raghunathan, R., Mohamed, A., Ahmed, H., & Hassan, Y. (2025). Severe Late-Onset Neutropenia in a Patient With Multiple Sclerosis Treated With Ocrelizumab. Cureus, 17(12), e99574. https://doi.org/10.7759/cureus.99574
PubMedID
41556007
Department(s)
Fellows and Residents
Document Type
Article